Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nithya Ramnath

Showing results (31-40 of 142) with videos related to

Pageof 15
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|February 27, 2010
The vitamin D/CYP24A1 story in cancerAmanda N King, David G Beer, Paul J Christensen, et al.
Chest|November 24, 2005
Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancerNithya Ramnath, Eric Sommers, Lary Robinson, et al.
Clinical Lung Cancer|March 24, 2026
Brief Report: Real-World Outcomes of Lurbinectedin in Veterans With Small Cell Lung CancerKatherine Curt, Reena Datta, Nithya Ramnath, et al.
Clinical Lung Cancer|November 19, 2023
Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient OutcomesMina Pirzadeh, Madeline Lagina, Cameron Wood, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 24, 2004
Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistryGeorge Deeb, Jianmin Wang, Nithya Ramnath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancerJoo-Heon Kim, Paul N Bogner, Nithya Ramnath, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2003
Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumorsNithya Ramnath, Gary N Schwartz, Patrick Smith, et al.
JTO Clinical and Research Reports|May 15, 2024
Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with <i>KRAS</i> G12C-Mutated NSCLCKatherine I Zhou, Chenyu Lin, Chin-Lin Tseng, et al.
Clinical Lung Cancer|April 4, 2017
Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung CancerAngel Qin, Lindsay Street, Kemp Cease, et al.
American Journal of Clinical Oncology|June 21, 2016
Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung CancerRadhika Raghunathan, Kemp Cease, Sandra Troeschel, et al.
Pageof 15

Showing results (31-40 of 142) with videos related to

Sort By:
Pageof 15
Anti-Cancer Agents in Medicinal Chemistry|February 27, 2010
The vitamin D/CYP24A1 story in cancerAmanda N King, David G Beer, Paul J Christensen, et al.
Chest|November 24, 2005
Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancerNithya Ramnath, Eric Sommers, Lary Robinson, et al.
Clinical Lung Cancer|March 24, 2026
Brief Report: Real-World Outcomes of Lurbinectedin in Veterans With Small Cell Lung CancerKatherine Curt, Reena Datta, Nithya Ramnath, et al.
Clinical Lung Cancer|November 19, 2023
Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient OutcomesMina Pirzadeh, Madeline Lagina, Cameron Wood, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 24, 2004
Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistryGeorge Deeb, Jianmin Wang, Nithya Ramnath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancerJoo-Heon Kim, Paul N Bogner, Nithya Ramnath, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2003
Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumorsNithya Ramnath, Gary N Schwartz, Patrick Smith, et al.
JTO Clinical and Research Reports|May 15, 2024
Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with <i>KRAS</i> G12C-Mutated NSCLCKatherine I Zhou, Chenyu Lin, Chin-Lin Tseng, et al.
Clinical Lung Cancer|April 4, 2017
Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung CancerAngel Qin, Lindsay Street, Kemp Cease, et al.
American Journal of Clinical Oncology|June 21, 2016
Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung CancerRadhika Raghunathan, Kemp Cease, Sandra Troeschel, et al.
Pageof 15